In a report released today, Mark Massaro from BTIG maintained a Buy rating on GeneDx Holdings (WGS – Research Report), with a price target of $19.00. The company’s shares closed yesterday at $11.00.
Massaro covers the Healthcare sector, focusing on stocks such as Adaptive Biotechnologies, DermTech, and GeneDx Holdings. According to TipRanks, Massaro has an average return of -17.2% and a 28.34% success rate on recommended stocks.
GeneDx Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $16.50.
WGS market cap is currently $288.7M and has a P/E ratio of -1.48.
Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of WGS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GeneDx Holdings (WGS) Company Description:
CM Life Sciences Inc is a blank check company.
Read More on WGS:
